{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05840224",
            "orgStudyIdInfo": {
                "id": "GS-US-616-6291"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-502070-16",
                    "type": "OTHER",
                    "domain": "European Medicines Agency"
                }
            ],
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of GS-4528 in Adults With Solid Tumors",
            "officialTitle": "A Phase 1 Study to Evaluate the Safety and Tolerability of GS-4528 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-gs-in-adults-with-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-21",
            "studyFirstSubmitQcDate": "2023-04-21",
            "studyFirstPostDateStruct": {
                "date": "2023-05-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gilead Sciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody.\n\nThe primary objectives of this study are:\n\n* To assess the safety and tolerability of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors.\n* To identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended Phase 2 dose (RP2D) of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 132,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1a: GS-4528 Monotherapy Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive escalating doses of GS-4528 monotherapy to determine the maximum tolerated dose.",
                    "interventionNames": [
                        "Biological: GS-4528"
                    ]
                },
                {
                    "label": "Phase 1a: GS-4528 Monotherapy Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive GS-4528 monotherapy at the dose determined in the escalation phase.",
                    "interventionNames": [
                        "Biological: GS-4528"
                    ]
                },
                {
                    "label": "Phase 1b:Dose Escalation of GS-4528 in Combination With Anti-PD-1 Monoclonal Antibody (zimberelimab)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive escalating doses of GS-4528 in combination with anti-PD1 monoclonal antibody (zimberelimab) to determine the maximum tolerated dose of GS-4528 as a combination therapy.",
                    "interventionNames": [
                        "Biological: GS-4528",
                        "Drug: Zimberelimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "GS-4528",
                    "description": "Administered intravenously",
                    "armGroupLabels": [
                        "Phase 1a: GS-4528 Monotherapy Dose Escalation",
                        "Phase 1a: GS-4528 Monotherapy Dose Expansion",
                        "Phase 1b:Dose Escalation of GS-4528 in Combination With Anti-PD-1 Monoclonal Antibody (zimberelimab)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Zimberelimab",
                    "description": "Administered intravenously.",
                    "armGroupLabels": [
                        "Phase 1b:Dose Escalation of GS-4528 in Combination With Anti-PD-1 Monoclonal Antibody (zimberelimab)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "First dose date up to 90 days post last dose (Up to 24 months)"
                },
                {
                    "measure": "Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)",
                    "timeFrame": "Day 1 up to 4 weeks"
                },
                {
                    "measure": "Maximum Tolerable Dose (MTD) of GS-4528",
                    "timeFrame": "Day 1 up to 4 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetic (PK) parameter: Cmax of GS-4528 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody",
                    "description": "Cmax is defined as the maximum observed concentration of drug.",
                    "timeFrame": "Predose on Day 1 and post dose up to end of treatment (EOT, Up to 24 months)"
                },
                {
                    "measure": "PK parameter: Cmin of GS-4528 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody",
                    "description": "Cmin is defined as the minimum observed concentration of drug.",
                    "timeFrame": "Predose on Day 1 and post dose up to EOT (Up to 24 months)"
                },
                {
                    "measure": "PK parameter: AUC of GS-4528 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody",
                    "description": "AUC is defined as the area under the concentration versus time curve.",
                    "timeFrame": "Predose on Day 1 and post dose up to EOT (Up to 24 months)"
                },
                {
                    "measure": "Serum Concentrations of GS-4528 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody",
                    "timeFrame": "Predose on Day 1 and post dose up to EOT (Up to 24 months)"
                },
                {
                    "measure": "Percentage of Participants who Develop Antidrug Antibody (ADA) Against GS-4528",
                    "timeFrame": "Predose on Day 1 and post dose up to 60 day follow-up (Up to 24 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Documented disease:\n\n  * Phase 1a dose escalation and backfill cohorts; Phase 1b dose escalation: Individuals with histologically or cytologically confirmed advanced solid tumors who have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy.\n  * Phase 1a dose expansion: Individuals with histologically or cytologically confirmed select indications who have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy.\n* Eastern Cooperative Oncology Group performance status 0 or 1.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.\n* Adequate organ function.\n* Individuals of childbearing potential who engage in heterosexual intercourse must agree to use method(s) of contraception.\n* Tissue requirements:\n\n  * Phase 1a dose escalation, Phase 1a dose expansion, and Phase 1b dose escalation: Must provide pre-treatment adequate tumor tissue sample prior to enrolment.\n  * Phase 1a backfill cohorts: Individuals must have fresh pre-treatment and on-treatment biopsy for biomarker analysis.\n* Life expectancy \u2265 3 months.\n\nKey Exclusion Criteria:\n\n* Positive serum pregnancy test or lactating female.\n* Prohibited concurrent anticancer therapy listed in the protocol.\n* Any anti-cancer therapy, whether investigational or approved, within protocol specified time prior to initiation of study including: major surgery (\\<28 days), immunotherapy or biologic therapy (\\< 28 days), chemotherapy (\\< 21 days), targeted small molecule therapy (\\< 14 days or \\< 5 half-lives whichever is shorter), hormonal therapy or other adjunctive therapy (\\< 14 days) or radiotherapy (\\< 21 days).\n* Any prior allogeneic tissue/solid organ transplantation, including allogeneic stem cell transplantation.\n* Diagnosis of immunodeficiency, either primary or acquired, or systemic steroid requirement of \\> 10 mg of prednisone or equivalent.\n* History of intolerance, hypersensitivity, or treatment discontinuation due to severe immune-related adverse events (irAEs) on prior immunotherapy.\n* History of autoimmune disease or active autoimmune disease that has required systemic treatment within 2 years prior to the start of study treatment.\n* Concurrent active second malignancy. Note: Individuals with a history of malignancy that have been completely treated, with no evidence of active cancer for 2 years prior to enrollment, or participants with surgically cured tumors with low risk of recurrence are allowed to enroll.\n* Have known active central nervous system (CNS) metastases and/ or carcinomatous meningitis.\n* Significant cardiovascular disease.\n* Have active serious infection requiring antibiotics.\n* Have active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).\n* History of pneumonitis, interstitial lung disease, or severe radiation pneumonitis (excluding localized radiation pneumonitis).\n* Symptomatic ascites or pleural effusion.\n* Live vaccines within 28 days of initiation of investigational product(s).\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gilead Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-833-445-3230 (GILEAD-0)",
                    "email": "GileadClinicalTrials@gilead.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gilead Study Director",
                    "affiliation": "Gilead Sciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Washington/FHCC",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "The Ottawa Hospital",
                    "status": "RECRUITING",
                    "city": "Ottawa",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "University Health Network, Princess Margaret Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "zip": "M5G 1Z5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital, Yonsei University Health Systems",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06273",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08023",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitari Vall D'Hebron- Oncology Service",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Taichung Veterans General Hospital",
                    "status": "RECRUITING",
                    "city": "Taichung",
                    "zip": "40705",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.1469,
                        "lon": 120.6839
                    }
                },
                {
                    "facility": "National Taiwan University Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei City",
                    "zip": "100229",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation",
                    "status": "RECRUITING",
                    "city": "Taoyuan",
                    "zip": "333",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.95233,
                        "lon": 121.20193
                    }
                },
                {
                    "facility": "St Bartholomew's Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "London",
                    "zip": "E1 1FR",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "The Royal Marsden NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "zip": "SM2 5PT",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study?nctid=NCT05840224"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}